- Details
- Oliver Sartor and Kambiz Rahbar discuss the RaLu study examining the safety and efficacy of sequential radiopharmaceutical treatments in metastatic castration-resistant prostate cancer. The discussion highlights how lutetium-PSMA therapy can be safely administered following radium treatment, with outcomes consistent across different treatment sequences and timing intervals. They examine how these...
|
- Details
- Oliver Sartor speaks with Russ Pachynski, Chris Maher, and Aadel Chaudhuri about their novel biomarker study in advanced prostate cancer. The discussion centers on their development of a cell-free DNA assay that examines both AR gene and enhancer alterations in mCRPC patients, showing significant prognostic value for treatment outcomes. Dr. Chaudhuri presents their discovery of a stemness signatur...
|
- Details
- Oliver Sartor speaks with Louise Emmett about combination therapy approaches with lutetium-PSMA in prostate cancer. The discussion explores various combination strategies, including promising results from the ENZA-p trial combining lutetium-PSMA with enzalutamide, which shows notable response rates in first-line mCRPC. They examine multiple potential combination approaches, including hormonal ther...
|
- Details
- Andrea Miyahira speaks with Ayesha Shafi about a study on AR coactivators CBP/p300 in prostate cancer. The research reveals that CBP/p300 expression increases as prostate cancer progresses to castration-resistant stages, correlating with poor patient survival. Through various preclinical studies, Dr. Shafi demonstrates that CBP/p300 plays a crucial role in DNA repair, particularly in homologous re...
|
- Details
- Ursula Vogl discusses key prostate cancer highlights from ESMO 2024. The conversation explores three major trials across different disease stages: the PATCH trial evaluating transdermal estradiol versus LHRH analogs in non-metastatic disease, the ARANOTE trial examining darolutamide in metastatic hormone-sensitive prostate cancer, and the PEACE-3 trial investigating radium-223 plus enzalutamide in...
|
- Details
- Rashid Sayyid and Zachary Klaassen discuss the resurgence of radium-223 in treating metastatic castration-resistant prostate cancer (mCRPC), focusing on the PEACE-3 trial results. The conversation begins with an overview of radium-223's mechanism as a targeted alpha emitter and its historical efficacy in the ALSYMPCA trial, before exploring its underutilization despite FDA approval. The discussion...
|
- Details
- Wilbert Zwart joins Neeraj Agarwal to discuss research on epigenetic targeting in prostate cancer. The discussion examines histone markers in metastatic castration-resistant prostate cancer (mCRPC) patients to predict response to enzalutamide treatment. Using patient-derived xenografts and computational modeling, the research identifies HDAC3 as a key target and demonstrates synergistic effects wh...
|
- Details
- Evan Yu joins Zachary Klaassen to discuss the results of the ARROW trial. The study evaluates Iodine-131-LNTH-1095, a novel PSMA radioligand therapy, in combination with enzalutamide versus enzalutamide alone for metastatic castration-resistant prostate cancer patients who previously received abiraterone. While the trial meets its primary endpoint with significantly higher PSA decline rates in the...
|
- Details
- Bram De Laere discusses the ProBio trial, a platform study for metastatic prostate cancer. Dr. De Laere explains the trial's unique design, which uses circulating tumor DNA analysis to guide treatment decisions and evaluate multiple biomarker-therapy combinations simultaneously. The study demonstrates that AR pathway inhibitors generally outperform taxane-based chemotherapy in mCRPC patients, with...
|
- Details
- While most patients with prostate cancer are diagnosed with localized disease, a subset will develop metastatic disease, and subsequently castration-resistant prostate cancer (mCRPC), which remains incurable. Additionally, an increasing number of patients will present with de novo metastatic prostate cancer, known as metastatic castration-sensitive prostate cancer (mCSPC), and may progress to mCRP...
|
